Gotowe bibliografie tematyczne / Pranlukast / Artykuły w czasopismach
Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Pranlukast.

Artykuły w czasopismach na temat „Pranlukast”

Autor: Grafiati
Data publikacji: 6 września 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Pranlukast”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 695 (kwiecień 1998): 11. http://dx.doi.org/10.2165/00128415-199806950-00038.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 743 (marzec 1999): 11–12. http://dx.doi.org/10.2165/00128415-199907430-00034.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 747 (kwiecień 1999): 10. http://dx.doi.org/10.2165/00128415-199907470-00030.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 1138 (luty 2007): 23. http://dx.doi.org/10.2165/00128415-200711380-00068.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Keam, Susan J., Katherine A. Lyseng-Williamson i Karen L. Goa. "Pranlukast". Drugs 63, nr 10 (2003): 991–1019. http://dx.doi.org/10.2165/00003495-200363100-00005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 865 (sierpień 2001): 11. http://dx.doi.org/10.2165/00128415-200108650-00032.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 876 (listopad 2001): 10. http://dx.doi.org/10.2165/00128415-200108760-00032.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

&NA;. "Pranlukast". Reactions Weekly &NA;, nr 987 (luty 2004): 13. http://dx.doi.org/10.2165/00128415-200409870-00039.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Kubota, Jun, Sho Takahashi, Takayuki Suzuki, Akira Ito, Naoe Akiyama i Noriko Takahata. "Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection". PLOS ONE 17, nr 5 (27.05.2022): e0269043. http://dx.doi.org/10.1371/journal.pone.0269043.

Pełny tekst źródła
Streszczenie:
Background In infants, respiratory syncytial virus (RSV) infection occasionally causes severe symptoms requiring respiratory support; however, supportive care is the primary treatment. This study compared the use of respiratory support among infants with RSV infection treated with or without pranlukast. Methods This retrospective cohort study included infants aged <10 months with RSV infection who were admitted to three secondary level hospitals in Japan between 2012 and 2019. The infants were divided into two groups depending on whether they were treated with pranlukast. The primary outcome was the receiving respiratory support (high-flow nasal cannula, nasal continuous positive airway pressure, or ventilator). The secondary outcomes were the length of hospital stay, and the Global Respiratory Severity Score (GRSS) on starting respiratory support or at the time of the worst signs during hospitalization. We performed a propensity score-matched analysis. Results A total of 492 infants, including 147 propensity score-matched pairs, were included in the analysis. The use of respiratory support was significantly lower in infants treated with pranlukast (3.4% [5/147]) than those treated without pranlukast (11.6% [17/147]; P = 0.01). In the propensity score-matched analysis, pranlukast use was associated with a significantly lower chance of needing respiratory support (odds ratio: 0.27, 95% confidence interval: 0.08–0.79; P = 0.01); however, the length of hospital stay (median: 4 days) and the GRSS (median: 2.804 and 2.869 for infants treated with and without pranlukast, respectively) did not differ significantly between propensity score-matched pairs. Conclusions Pranlukast use was associated with a reduced likelihood of requiring respiratory support in infants aged <10 months with RSV infection.
Style APA, Harvard, Vancouver, ISO itp.
10

Figueroa, Eric E., Meghan Kramer, Kevin Strange i Jerod S. Denton. "CysLT1 receptor antagonists pranlukast and zafirlukast inhibit LRRC8-mediated volume regulated anion channels independently of the receptor". American Journal of Physiology-Cell Physiology 317, nr 4 (1.10.2019): C857—C866. http://dx.doi.org/10.1152/ajpcell.00281.2019.

Pełny tekst źródła
Streszczenie:
Volume-regulated anion channels (VRACs) encoded by the leucine-rich repeat containing 8 ( LRRC8) gene family play critical roles in myriad cellular processes and might represent druggable targets. The dearth of pharmacological compounds available for studying VRAC physiology led us to perform a high-throughput screen of 1,184 of US Food and Drug Administration-approved drugs for novel VRAC modulators. We discovered the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, pranlukast, as a novel inhibitor of endogenous VRAC expressed in human embryonic kidney 293 (HEK293) cells. Pranlukast inhibits VRAC voltage-independently, reversibly, and dose-dependently with a maximal efficacy of only ~50%. The CysLT1R pathway has been implicated in activation of VRAC in other cell types, prompting us to test whether pranlukast requires the CysLT1R for inhibition of VRAC. Quantitative PCR analysis demonstrated that CYSLTR1 mRNA is virtually undetectable in HEK293 cells. Furthermore, the CysLT1R agonist leukotriene D4 had no effect on VRAC activity and failed to stimulate Gq-coupled receptor signaling. Heterologous expression of the CysLT1R reconstituted LTD4-CysLT1R- Gq-calcium signaling in HEK293 cells but had no effect on VRAC inhibition by pranlukast. Finally, we show the CysLT1R antagonist zafirlukast inhibits VRAC with an IC50 of ~17 µM and does so with full efficacy. Our data suggest that both pranlukast and zafirlukast are likely direct channel inhibitors that work independently of the CysLT1R. This study provides clarifying insights into the putative role of leukotriene signaling in modulation of VRAC and identifies two new chemical scaffolds that can be used for development of more potent and specific VRAC inhibitors.
Style APA, Harvard, Vancouver, ISO itp.
11

Kim, Seo W., Hunam Kim, Yon J. Ryu, Jin H. Lee, Sung S. Shim, Yoo K. Kim i Jung H. Chang. "Efficacy and Safety of Modified Pranlukast (Prakanon®) Compared with Pranlukast (Onon®): A Randomized, Open-Label, Crossover Study". Open Respiratory Medicine Journal 10, nr 1 (30.06.2016): 36–45. http://dx.doi.org/10.2174/1874306401610010036.

Pełny tekst źródła
Streszczenie:
Introduction: Pranlukast is a leukotriene receptor antagonist (LTRA) that is used as an additional controller of mild to moderate asthma. This study compared the efficacy and side effects of two bioequivalent preparations of pranlukast: original pranlukast (Onon®; Ono Pharmaceutical, Japan) and a modified formulation of pranlukast (Prakanon®; Yuhan Co, Korea) in patients with mild to moderate asthma. Methods: Of the 34 subjects screened, 30 patients who were using standard medication to control asthma and scored less than 20 points on the Asthma Control Test™ (ACT) were assigned randomly to one of the two groups in a prospective, open label, crossover study: group 1 received Prakanon® (150 mg/day) and group 2 received Onon® (450 mg/day) for 8 weeks each; after a 1-week rest period, the groups were switched to the alternative medication for further 8 weeks and monitored for 2 more weeks without study medication. Evaluation parameters included the ACT, quality of life questionnaire adult Korean asthmatics (QLQAKA), pulmonary function tests, peripheral blood tests, vital signs, and adverse events. Results: Thirty patients were enrolled and 21 completed the trial: 10 in group 1 and 11 in group 2. The baseline data of the two groups did not differ. No statistical significant differences were observed in efficacy and lung function at each time and in changes from baseline value between the two kinds of pranlukast. The final asthma control rate was 81% with Prakanon® and 76% with Onon®. There were no differences in vital signs and laboratory data at each time and in changes from baseline value between the two drugs. There were no differences in adverse events between the two drugs. The most common side effect was abdominal pain. Drug compliance was high, without differences between the two drugs. Conclusion: These findings suggest that Prakanon® which is an improved formulation of pranlukast at a lower dose than the original formulation, Onon®, has a similar efficacy and side effect profile in the control of persistent asthma.
Style APA, Harvard, Vancouver, ISO itp.
12

&NA;. "Montelukast/pranlukast/zafirlukast". Reactions Weekly &NA;, nr 967 (wrzesień 2003): 12. http://dx.doi.org/10.2165/00128415-200309670-00040.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

Yelamanchi, Soujanya D., Sumaithangi Thattai Arun Kumar, Archita Mishra, Thottethodi Subrahmanya Keshava Prasad i Avadhesha Surolia. "Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis". Molecules 27, nr 5 (24.02.2022): 1520. http://dx.doi.org/10.3390/molecules27051520.

Pełny tekst źródła
Streszczenie:
Mycobacterium tuberculosis has been infecting millions of people worldwide over the years, causing tuberculosis. Drugs targeting distinct cellular mechanisms including synthesis of the cell wall, lipids, proteins, and nucleic acids in Mtb are currently being used for the treatment of TB. Although extensive research is being carried out at the molecular level in the infected host and pathogen, the identification of suitable drug targets and drugs remains under explored. Pranlukast, an allosteric inhibitor of MtArgJ (Mtb ornithine acetyltransferase) has previously been shown to inhibit the survival and virulence of Mtb. The main objective of this study was to identify the altered metabolic pathways and biological processes associated with the differentially expressed metabolites by PRK in Mtb. Here in this study, metabolomics was carried out using an LC-MS/MS-based approach. Collectively, 50 metabolites were identified to be differentially expressed with a significant p-value through a global metabolomic approach using a high-resolution mass spectrometer. Metabolites downstream of argJ were downregulated in the arginine biosynthetic pathway following pranlukast treatment. Predicted human protein interactors of pranlukast-treated Mtb metabolome were identified in association with autophagy, inflammation, DNA repair, and other immune-related processes. Further metabolites including N-acetylglutamate, argininosuccinate, L-arginine, succinate, ergothioneine, and L-phenylalanine were validated by multiple reaction monitoring, a targeted mass spectrometry-based metabolomic approach. This study facilitates the understanding of pranlukast-mediated metabolic changes in Mtb and holds the potential to identify novel therapeutic approaches using metabolic pathways in Mtb.
Style APA, Harvard, Vancouver, ISO itp.
14

Yonetomi, Y., M. Fujita, N. Nakagawa i T. Obata. "Preclinical pharmacology of pranlukast". Clinical & Experimental Allergy Reviews 1, nr 3 (listopad 2001): 210–17. http://dx.doi.org/10.1046/j.1472-9725.2001.t01-1-00008.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

&NA;. "Pranlukast protects against deteriorating asthma control". Inpharma Weekly &NA;, nr 1086 (maj 1997): 16. http://dx.doi.org/10.2165/00128413-199710860-00031.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Iikura, Y., K. Miura, Y. Odajima, T. Imai, H. Sugimoto i M. Ebisawa. "Efficacy of pranlukast in childhood asthma". Clinical & Experimental Allergy Reviews 1, nr 3 (listopad 2001): 287–96. http://dx.doi.org/10.1046/j.1472-9725.2001.t01-1-00014.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

&NA;. "Pranlukast demonstrates long-term efficacy in asthma". Inpharma Weekly &NA;, nr 1303 (wrzesień 2001): 6. http://dx.doi.org/10.2165/00128413-200113030-00015.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

Kim, Sujeong, i Jong-Myung Lee. "A Case of Pranlukast-Induced Anaphylactic Shock". Allergy, Asthma & Immunology Research 8, nr 3 (2016): 276. http://dx.doi.org/10.4168/aair.2016.8.3.276.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

Yang, X. X., W. S. Powell, L. J. Xu i J. G. Martin. "Strain dependence of the airway response to dry-gas hyperpnea challenge in the rat". Journal of Applied Physiology 86, nr 1 (1.01.1999): 152–58. http://dx.doi.org/10.1152/jappl.1999.86.1.152.

Pełny tekst źródła
Streszczenie:
The aim of the study was to investigate strain dependence and mechanisms of airway responses to dry-gas hyperpnea challenge in the rat. We studied responses in a strain that is hyperresponsive to methacholine, Fischer 344 (F-344); in two normoresponsive strains, Lewis and ACI; and in an atopic but normoresponsive strain, Brown Norway (BN). We examined the effects of a neurokinin (NK) 1-receptor (CP-99994), an NK2-receptor (SR-48968), and a leukotriene D4(LTD4)-receptor antagonist (pranlukast) on responses to hyperpnea challenge in BN rats. The animals were ventilated with a tidal volume of 8 ml/kg and a frequency of 150 breaths/min with either a dry or humidified mixture of 5% CO2-95% O2 for 5 min for hyperpnea challenge, whereas responses to challenge were measured during spontaneous breathing. Pulmonary resistance increased after dry-gas challenge in BN and ACI but not in F-344 and Lewis rats. CP-99994, SR-48968, and pranlukast significantly attenuated the increase in pulmonary resistance after dry-gas challenge. There were no significant differences in responsiveness to airway challenge with LTD4 among the BN, F-344 and ACI rats. We conclude that responses to dry-gas hyperpnea challenge are strain dependent in rats and are mediated by NKs and LTD4.
Style APA, Harvard, Vancouver, ISO itp.
20

Tsuji, Yuichirou, Kenji Narui, Takaaki Takayanagi, Hiroshi Chikaoka, Seiji Takita, Youji Iikura i Tadasu Sakai. "Effectiveness of pranlukast hydrate for Henoch-Schoenlein purpura." Nihon Shoni Jinzobyo Gakkai Zasshi 11, nr 2 (1998): 185–90. http://dx.doi.org/10.3165/jjpn.11.185.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

Theron, A. J., H. C. Steel, G. R. Tintinger, C. M. Gravett, R. Anderson i C. Feldman. "Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function". Journal of Immunology Research 2014 (2014): 1–16. http://dx.doi.org/10.1155/2014/608930.

Pełny tekst źródła
Streszczenie:
Cysteinyl leukotrienes (cysLTs) are produced predominantly by cells of the innate immune system, especially basophils, eosinophils, mast cells, and monocytes/macrophages. Notwithstanding potent bronchoconstrictor activity, cysLTs are also proinflammatory consequent to their autocrine and paracrine interactions with G-protein-coupled receptors expressed not only on the aforementioned cell types, but also on Th2 lymphocytes, as well as structural cells, and to a lesser extent neutrophils and CD8+cells. Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast. More recently these agents have also been reported to possess secondary anti-inflammatory activities, distinct from cysLTR1 antagonism, which appear to be particularly effective in targeting neutrophils and monocytes/macrophages. Underlying mechanisms include interference with cyclic nucleotide phosphodiesterases, 5′-lipoxygenase, and the proinflammatory transcription factor, nuclear factor kappa B. These and other secondary anti-inflammatory mechanisms of the commonly used cysLTR1 antagonists are the major focus of the current review, which also includes a comparison of the anti-inflammatory effects of montelukast, pranlukast, and zafirlukast on human neutrophilsin vitro, as well as an overview of both the current clinical applications of these agents and potential future applications based on preclinical and early clinical studies.
Style APA, Harvard, Vancouver, ISO itp.
22

&NA;. "Pranlukast was found to be 'safe and well tolerated'". Reactions Weekly &NA;, nr 667 (wrzesień 1997): 4. http://dx.doi.org/10.2165/00128415-199706670-00009.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

Matsuse, Hiroto, i Shigeru Kohno. "Leukotriene receptor antagonists pranlukast and montelukast for treating asthma". Expert Opinion on Pharmacotherapy 15, nr 3 (19.12.2013): 353–63. http://dx.doi.org/10.1517/14656566.2014.872241.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

Schurman, Scott J., Janice M. Alderman, Marc Massanari, Atilano G. Lacson i Sharon A. Perlman. "Tubulointerstitial Nephritis Induced by the Leukotriene Receptor Antagonist Pranlukast". Chest 114, nr 4 (październik 1998): 1220–23. http://dx.doi.org/10.1378/chest.114.4.1220.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

Kobayashi, Shigeto, Shyugo Ishizuka, Naoto Tamura, Makiyo Takaya, Kazuhiko Kaneda i Hiroshi Hashimoto. "Churg?Strauss syndrome (CSS) in a patient receiving pranlukast". Clinical Rheumatology 22, nr 6 (1.12.2003): 491–92. http://dx.doi.org/10.1007/s10067-003-0791-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

Shimbo, Junsuke, Osamu Onodera, Keiko Tanaka i Shoji Tsuji. "Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast". Clinical Rheumatology 24, nr 6 (2.12.2004): 661–62. http://dx.doi.org/10.1007/s10067-004-1035-z.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

Schierle, Simone, Jurema Schmidt, Astrid Kaiser i Daniel Merk. "Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators". ChemMedChem 13, nr 23 (20.11.2018): 2530–45. http://dx.doi.org/10.1002/cmdc.201800549.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Hao, Yanli, Lan Wang, Jun Li, Nan Liu, Jinfeng Feng, Mojiao Zhao i Xiaoning Zhang. "Enhancement of Solubility, Transport Across Madin-Darby Canine Kidney Monolayers and Oral Absorption of Pranlukast Through Preparation of a Pranlukast-Phospholipid Complex". Journal of Biomedical Nanotechnology 11, nr 3 (1.03.2015): 469–77. http://dx.doi.org/10.1166/jbn.2015.1914.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Yoshida, Ishizaki, Shoji, Onuma, Nakagawa, Nakabayashi, Akahori, Hasegawa i Amayasu. "Effect of pranlukast on bronchial inflammation in patients with asthma". Clinical & Experimental Allergy 30, nr 7 (lipiec 2000): 1008–14. http://dx.doi.org/10.1046/j.1365-2222.2000.00834.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

SAKAGUCHI, KAZUO, JUNKO KUWABARA, AKIYO SAITOU, EMIKO MIYASHITA, YOSHIAKI TAKAYAMA, MASAHIRO AIZAKI, HISAO KUMAKURA, SHOICHI TANGE i SHUICHI ICHIKAWA. "The Pharmacokinetic Interaction between Theophylline and Leukotriene Receptor Antagonist, Pranlukast." Japanese Journal of Hospital Pharmacy 23, nr 6 (1997): 507–11. http://dx.doi.org/10.5649/jjphcs1975.23.507.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Watanabe, Toru, Yasufumi Iinuma, Shin-ichi Naito i Koju Nitta. "Eosinophilic tumor in a patient with bronchial asthma receiving pranlukast". European Journal of Pediatrics 166, nr 2 (17.08.2006): 183–84. http://dx.doi.org/10.1007/s00431-006-0226-9.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Nakade, Susumu, Akinori Yamauchi, Junji Komaba, Tomoya Ohno, Junsaku Kitagawa, Naoki Honda, Chihiro Hasegawa i in. "Effect of Clarithromycin on the Pharmacokinetics of Pranlukast in Healthy Volunteers". Drug Metabolism and Pharmacokinetics 23, nr 6 (2008): 428–33. http://dx.doi.org/10.2133/dmpk.23.428.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Yoshifuku, Kousuke, Shoji Matsune i Yuichi Kurono. "The Efficacy of Pranlukast Hydrate for Chronic Sinusitis with Nasal Polyp". Practica Oto-Rhino-Laryngologica 101, nr 9 (2008): 715–20. http://dx.doi.org/10.5631/jibirin.101.715.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

Kim, Hyeong-Eun, Jun-Seok Hwang, Sun-Hang Cho, Young-Jin Kim i Kang-Moo Huh. "Preparation and Characterization of Poly(ethylene glycol) Based Pranlukast Solid Dispersion". Polymer Korea 36, nr 1 (25.01.2012): 41–46. http://dx.doi.org/10.7317/pk.2012.36.1.041.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

UNDERWOOD, D., S. BOCHNOWICZ, R. OSBORN, S. NEWSHOLME, T. TORPHY i D. HAY. "426 The cysteinyl-leukotriene (CysLT) receptor antagonist, pranlukast, attenuates airway inflammation". Journal of Allergy and Clinical Immunology 97, nr 1 (styczeń 1996): 289. http://dx.doi.org/10.1016/s0091-6749(96)80644-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Brocks, D. R., J. W. Upward, P. Georgiou, G. Stelman, E. Doyle, E. Allen, P. Wyld i M. J. Dennis. "The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers". European Journal of Clinical Pharmacology 51, nr 3-4 (12.12.1996): 303–8. http://dx.doi.org/10.1007/s002280050202.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

Kanazawa, Hiroshi. "Effects of Pranlukast on Vascular Endothelial Growth Factor Levels in Asthma". Chest 127, nr 4 (kwiecień 2005): 1461. http://dx.doi.org/10.1016/s0012-3692(15)34509-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

Sun, Tao, Zhihua Wu, Mengyao Luo, Donghai Lin i Chenyun Guo. "Pranlukast, a novel binding ligand of human Raf1 kinase inhibitory protein". Biotechnology Letters 38, nr 8 (5.05.2016): 1375–80. http://dx.doi.org/10.1007/s10529-016-2117-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
39

Kanazawa, Hiroshi. "Effects of Pranlukast on Vascular Endothelial Growth Factor Levels in Asthma". CHEST Journal 127, nr 4 (1.04.2005): 1461. http://dx.doi.org/10.1378/chest.127.4.1461.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
40

Baek, In-hwan, Jung-Soo Kim, Eun-Sol Ha, Gwang-Ho Choo, Wonkyung Cho, Sung-Joo Hwang i Min-Soo Kim. "Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose". International Journal of Biological Macromolecules 67 (czerwiec 2014): 53–57. http://dx.doi.org/10.1016/j.ijbiomac.2014.03.006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
41

Takahashi, Yukitoshi, Katsumi Imai, Hitoshi Ikeda, Yuko Kubota, Etsuko Yamazaki i Fuminobu Susa. "Open study of pranlukast add-on therapy in intractable partial epilepsy". Brain and Development 35, nr 3 (marzec 2013): 236–44. http://dx.doi.org/10.1016/j.braindev.2012.04.001.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

TAKAHASHI, Naotsugu, Tomoaki IWANAGA, Hisamichi AIZAWA, Hiroshi KOTO, Kentaroh WATANABE, Reiko KISHIKAWA, Togo IKEDA, Shunsuke SHOJI, Sankei NISHIMA i Nobuyuki KARA. "Acute Interstitial Pneumonia Induced by ONO-1078 (pranlukast), a Leukotriene Receptor Antagonist." Internal Medicine 40, nr 8 (2001): 791–94. http://dx.doi.org/10.2169/internalmedicine.40.791.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

Lee, Sin Hyung, Jae Jeong Shim, Kyung Kyu Kim, Hye Cheol Jeong, Young Hwan Kwon, Je Hyeong Kim, Sung Yong Lee i in. "Effects of pranlukast on ovalbumin induced early-phase bronchoconstriction in guinea pigs". Tuberculosis and Respiratory Diseases 46, nr 5 (1999): 697. http://dx.doi.org/10.4046/trd.1999.46.5.697.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
44

KOBAYASHI, Maiko, Takako MASUDA, Yusuke KINOSHITA i Hiroyuki HARA. "Churg-Strauss Syndrome in a Patient Receiving Pranlukast as Treatment for Asthma". Nishi Nihon Hifuka 67, nr 4 (2005): 319–22. http://dx.doi.org/10.2336/nishinihonhifu.67.319.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
45

Endo, Shuichiro, Minoru Gotoh, Kimihiro Okubo, Kazuhiro Hashiguchi, Hidenori Suzuki i Keisuke Masuyama. "Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber". Journal of Drug Assessment 1, nr 1 (22.02.2012): 48–54. http://dx.doi.org/10.3109/21556660.2012.703630.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
46

Velázquez-Quesada, Inés, Angel J. Ruiz-Moreno, Diana Casique-Aguirre, Charmina Aguirre-Alvarado, Fabiola Cortés-Mendoza, Marisol de la Fuente-Granada, Carlos García-Pérez i in. "Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells". Drug Design, Development and Therapy Volume 14 (maj 2020): 1799–811. http://dx.doi.org/10.2147/dddt.s247730.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
47

Ichiyama, T., S. Hasegawa, M. Umeda, K. Terai, T. Matsubara i S. Furukawa. "Pranlukast inhibits NF-κB activation in human monocytes/macrophages and T cells". Clinical & Experimental Allergy 33, nr 6 (czerwiec 2003): 802–7. http://dx.doi.org/10.1046/j.1365-2222.2003.01673.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

Inoue, Ryosuke, Takahide Teramoto, Susumu Nakade, Hiroyuki Okamoto, Eiji Yukawa, Shun Higuchi, Naomi Kondo i Haruki Mikawa. "Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma". Allergology International 52, nr 4 (2003): 213–18. http://dx.doi.org/10.1046/j.1323-8930.2003.00304.x.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

Horiguchi, Takahiko, Soichi Tachikawa, Rieko Kondo, Junichi Miyazaki, Yasushi Sasaki, Kengo Banno i Misuzu Handa. "Evaluation of the Combined Effect of Pranlukast during High-dose Steroid Inhalation". Arzneimittelforschung 52, nr 11 (26.12.2011): 813–16. http://dx.doi.org/10.1055/s-0031-1299972.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

Nagata, Makoto, Keiko Saito, Izumi Kikuchi, Koichi Hagiwara i Minoru Kanazawa. "Effect of the Cysteinyl Leukotriene Antagonist Pranlukast on Transendothelial Migration of Eosinophils". International Archives of Allergy and Immunology 137, nr 1 (2005): 2–6. http://dx.doi.org/10.1159/000085424.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii